Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis

Sara Verazza, Giorgia Negro, Denise Marafon, Alessandro Consolaro, Alberto Martini, Angelo Ravelli

Research output: Contribution to journalArticle

Abstract

Several studies have examined effects of discontinuing treatment after clinical remission in children with JIA. So far, only methotrexate and tumour necrosis factor a (TNF) inhibitors have been investigated. Overall, the relapse rate after termination of these medications was substantial. However, with the exception of one controlled trial of methotrexate, all analyses are retrospective. In addition, the results obtained for TNF-a inhibitors are variable and conclusions of existing studies are often divergent. No consistent predictors of the risk of flare were identified. Some evidence exists that low doses of medications may be sufficient to maintain remission. Because achievement of inactive disease has become increasingly more common in paediatric rheumatology practice, evidence-based data and expert recommendations to guide drug discontinuation are needed. This information should help to avoid both the risks and costs of prolonged therapy and to minimise the likelihood of disease flares. It should also be clarified whether it is more advantageous to stop treatment abruptly or to taper it gradually by reducing the dosage progressively or by increasing the interval between doses. Another key objective for future studies is to identify predictors of disease flare after treatment discontinuation. In addition, the optimal policy for discontinuation of other biologic medications used in children with JIA, such as anakinra, abatacept, tocilizumab, and canakinumab, should be established.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume31
Issue numberSUPPL.78
Publication statusPublished - 2013

Fingerprint

Juvenile Arthritis
Methotrexate
Tumor Necrosis Factor-alpha
Interleukin 1 Receptor Antagonist Protein
Evidence-Based Practice
Rheumatology
Therapeutics
Pediatrics
Costs and Cost Analysis
Recurrence
Pharmaceutical Preparations

Keywords

  • Inactive disease
  • Juvenile idiopathic arthritis
  • Medication withdrawal
  • Remission
  • Treatment discontinuation

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis. / Verazza, Sara; Negro, Giorgia; Marafon, Denise; Consolaro, Alessandro; Martini, Alberto; Ravelli, Angelo.

In: Clinical and Experimental Rheumatology, Vol. 31, No. SUPPL.78, 2013.

Research output: Contribution to journalArticle

@article{e4e7ef49aab04aa683cdedf9f6128235,
title = "Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis",
abstract = "Several studies have examined effects of discontinuing treatment after clinical remission in children with JIA. So far, only methotrexate and tumour necrosis factor a (TNF) inhibitors have been investigated. Overall, the relapse rate after termination of these medications was substantial. However, with the exception of one controlled trial of methotrexate, all analyses are retrospective. In addition, the results obtained for TNF-a inhibitors are variable and conclusions of existing studies are often divergent. No consistent predictors of the risk of flare were identified. Some evidence exists that low doses of medications may be sufficient to maintain remission. Because achievement of inactive disease has become increasingly more common in paediatric rheumatology practice, evidence-based data and expert recommendations to guide drug discontinuation are needed. This information should help to avoid both the risks and costs of prolonged therapy and to minimise the likelihood of disease flares. It should also be clarified whether it is more advantageous to stop treatment abruptly or to taper it gradually by reducing the dosage progressively or by increasing the interval between doses. Another key objective for future studies is to identify predictors of disease flare after treatment discontinuation. In addition, the optimal policy for discontinuation of other biologic medications used in children with JIA, such as anakinra, abatacept, tocilizumab, and canakinumab, should be established.",
keywords = "Inactive disease, Juvenile idiopathic arthritis, Medication withdrawal, Remission, Treatment discontinuation",
author = "Sara Verazza and Giorgia Negro and Denise Marafon and Alessandro Consolaro and Alberto Martini and Angelo Ravelli",
year = "2013",
language = "English",
volume = "31",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "SUPPL.78",

}

TY - JOUR

T1 - Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis

AU - Verazza, Sara

AU - Negro, Giorgia

AU - Marafon, Denise

AU - Consolaro, Alessandro

AU - Martini, Alberto

AU - Ravelli, Angelo

PY - 2013

Y1 - 2013

N2 - Several studies have examined effects of discontinuing treatment after clinical remission in children with JIA. So far, only methotrexate and tumour necrosis factor a (TNF) inhibitors have been investigated. Overall, the relapse rate after termination of these medications was substantial. However, with the exception of one controlled trial of methotrexate, all analyses are retrospective. In addition, the results obtained for TNF-a inhibitors are variable and conclusions of existing studies are often divergent. No consistent predictors of the risk of flare were identified. Some evidence exists that low doses of medications may be sufficient to maintain remission. Because achievement of inactive disease has become increasingly more common in paediatric rheumatology practice, evidence-based data and expert recommendations to guide drug discontinuation are needed. This information should help to avoid both the risks and costs of prolonged therapy and to minimise the likelihood of disease flares. It should also be clarified whether it is more advantageous to stop treatment abruptly or to taper it gradually by reducing the dosage progressively or by increasing the interval between doses. Another key objective for future studies is to identify predictors of disease flare after treatment discontinuation. In addition, the optimal policy for discontinuation of other biologic medications used in children with JIA, such as anakinra, abatacept, tocilizumab, and canakinumab, should be established.

AB - Several studies have examined effects of discontinuing treatment after clinical remission in children with JIA. So far, only methotrexate and tumour necrosis factor a (TNF) inhibitors have been investigated. Overall, the relapse rate after termination of these medications was substantial. However, with the exception of one controlled trial of methotrexate, all analyses are retrospective. In addition, the results obtained for TNF-a inhibitors are variable and conclusions of existing studies are often divergent. No consistent predictors of the risk of flare were identified. Some evidence exists that low doses of medications may be sufficient to maintain remission. Because achievement of inactive disease has become increasingly more common in paediatric rheumatology practice, evidence-based data and expert recommendations to guide drug discontinuation are needed. This information should help to avoid both the risks and costs of prolonged therapy and to minimise the likelihood of disease flares. It should also be clarified whether it is more advantageous to stop treatment abruptly or to taper it gradually by reducing the dosage progressively or by increasing the interval between doses. Another key objective for future studies is to identify predictors of disease flare after treatment discontinuation. In addition, the optimal policy for discontinuation of other biologic medications used in children with JIA, such as anakinra, abatacept, tocilizumab, and canakinumab, should be established.

KW - Inactive disease

KW - Juvenile idiopathic arthritis

KW - Medication withdrawal

KW - Remission

KW - Treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=84885746495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885746495&partnerID=8YFLogxK

M3 - Article

C2 - 24129147

AN - SCOPUS:84885746495

VL - 31

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - SUPPL.78

ER -